U.S. Markets closed

Artelo Biosciences, Inc. (ARTL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8190-0.0110 (-1.33%)
At close: 4:00PM EDT
0.8200 0.00 (0.12%)
After hours: 07:55PM EDT

Artelo Biosciences, Inc.

888 Prospect Street
Suite 210
La Jolla, CA 92037
United States
760 943 1689

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory D. GorgasPres, CEO, CFO, Treasurer, Sec. & Director581.44kN/A1963
Mr. Randy SchreckhiseVP of Fin. & OperationsN/AN/AN/A
Dr. Andrew Yates Ph.D.Sr. VP, Chief Scientific Officer & Member of Scientific Advisor BoardN/AN/AN/A
Mr. Peter Michael O'BrienSr. VP of European OperationsN/AN/A1978
Dr. Steven D. ReichChief Medical OfficerN/AN/A1946
Mr. Jason H. BaybuttSr. VP of Fin.N/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.

Corporate Governance

Artelo Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.